Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO. Neurol Neuroimmunol Neuroinflamm 2015;2:e134; doi: 10.1212/NXI.0000000000000134 GLOSSARY AQP4 5 aquaporin-4; BAFF 5 B-cell activating factor; BBB 5 blood-brain barrier; CBA 5 cell-based assay; GFAP 5 glial fibrillary acidic protein; ICAM-1 5 intercellular adhesion molecule-1; IFN 5 interferon; IL 5 interleukin; MMP-9 5 matrix metalloproteinase-9; MOG 5 myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NF 5 neurofilament; NMO 5 neuromyelitis optica; NMOSD 5 NMO spectrum disorder; ON 5 optic neuritis; OSMS 5 opticospinal MS; T H 5 T helper cell; VCAM-1 5 vascular cell adhesion molecule-1; VEGF-A 5 vascular endothelial growth factor-A.
Presence of AQP4-IgG has also facilitated the diagnosis and early treatment of patients with NMO/NMOSD. However, studies correlating serum AQP4-IgG titers with disease activity, severity, outcome, and response to therapy have yielded inconsistent results. [13] [14] [15] The search for additional biomarker candidates in NMO has resulted in several interesting leads, though they remain to be further validated. 16, 17 In this article, we will review the current landscape of biomarker(s)/biomarker candidates in NMO and NMOSD, consider their clinical implications, and propose potential analytic platforms for future NMO biomarker discovery, validation, and application.
DESIGN OF LITERATURE REVIEW Along with manual literature review by authors with expertise in the field, published peer-reviewed articles were interrogated to assess the current knowledge about biomarkers in NMO/NMOSD. A search of the PubMed database (National Center for Biotechnology Information, US National Library of Medicine) was performed using the query terms "biomarker," "NMO," "opticospinal multiple sclerosis (OSMS)," "blood," "serum," and "CSF." NMO and NMOSD met the criteria proposed by Wingerchuk et al. 18 The analysis included published literature up to 2014. Although it was not possible to cite every published report in this review, all of the meritorious efforts to discover and validate potential biomarkers in NMO/ NMOSD are appreciated. Every effort was made to highlight universally accepted themes. See the figure for a summary of biomarker candidates in NMO and MS and their current evidence levels.
I. AQP4-IGG AND OTHER SEROLOGIC MARKERS
AQP4-IgG/NMO-IgG. AQP4-IgG was the first proposed biomarker of NMO/NMOSD and has become a sine qua non of NMO diagnosis. Given
Figure
Summary of relative biomarkers candidate levels in CSF and sera of NMO and MS patients its high specificity, NMO-IgG was added as a supportive criterion in the revised 2006 NMO diagnostic criteria. 18 To date, AQP4 is the main clinically approved biomarker for NMO. AQP4, the most abundant water channel in the CNS, is found predominantly on astrocyte foot processes forming the glia limitans of the blood-brain barrier (BBB) and around synapses at nodes of Ranvier. 19 The AQP4 protein is highly expressed in the brainstem, hypothalamus, diencephalon, spinal cord, and optic nerves, correlating with the frequent distribution of NMO lesions. 20 AQP4 is also found in kidney, stomach, placenta, and more isolated regions of the CNS (such as granular layer of the cerebellum, hippocampus, and globus pallidus), but most of these tissues are not known to be involved in NMO/ NMOSD. 21, 22 Extensive experimental evidence supports an important contribution of AQP4-IgG to disease pathogenesis. [23] [24] [25] [26] It is evident that NMO-IgG from the systemic circulation enters the CNS through a disrupted BBB; however, it is also possible that anti-APQ4 is generated intrathecally. 24, 25, 27 The latter scenario has implications for potential detection of AQP4-IgG in CSF vs serum. AQP4-IgG (primarily IgG1 subclass) binds avidly to AQP4, resulting in complement fixation, generation of chemotactic signals (e.g., C3a, C5a), immune cell infiltration, and subsequent loss of AQP4 and glial fibrillary acidic protein (GFAP) in astrocytes. [28] [29] [30] [31] Detection of AQP4-IgG has improved over the past decade. First-generation tissue-based immunofluorescence assays had relatively low sensitivity (48%-54% for a single assay or 72% in a combination assay using recombinant human AQP4 ELISA and transfected cell-based assays [CBAs] ) and specificity of up to 100%. [32] [33] [34] Newer techniques, such as optimized immunohistochemistry assay, can detect AQP4-IgG with 74.8% sensitivity and 100% specificity. 35 Antibody directed against the M23 isoform of AQP4 in orthogonal arrays has been reported to have the highest sensitivity for the diagnosis of NMO/ NMOSD. 36 Live CBAs, particularly those using the M1-AQP4 isoform as antigen, have had the lowest false-positive rates. 37 The importance of assay methodology for the differential diagnosis of NMO vs MS has recently been underscored by the findings of Pittock et al., 38 suggesting caution in interpretation of results obtained using ELISA.
AQP4-IgG assessment can be helpful with disease monitoring in certain cases. AQP4-IgG is found in 74% of recurrent NMO cases, 39 and initial seropositivity correlates with higher relapse rates than seronegative status. 9 Of interest, AQP4-IgG can predate clinical symptoms by up to 10 years. 40 Patients with NMO often benefit from plasmapheresis, presumably due to reduction in circulating AQP4-IgG and/or other circulating soluble factor(s). 41, 42 However, the utility of monitoring AQP4-IgG titers during a distinct clinical relapse is less clear. AQP4-IgG titers also may not predict extent of spinal disease. 14, 43 Immunosuppressive therapies (such as azathioprine, cyclophosphamide, or rituximab) can lower AQP4-IgG titers during remission; however, disease quiescence can occur with persistently high NMO-IgG titers. 44 Currently, NMO-IgG titers do not appear to be a reliable indicator of disease activity or prognosis. Larger longitudinal studies will establish criteria for and usefulness of serial NMO-IgG testing.
Despite the clinical utility of AQP4-IgG in NMO diagnosis, several caveats preclude its use as a universal NMO biomarker. Approximately 20%-30% of patients with the clinical syndrome of NMO lack detectable AQP4-IgG, while in older studies up to 5%-10% of patients with MS were AQP4-IgG positive; however, seronegative cases have significantly decreased with the use of newer CBAs.
9,45 AQP4-IgG seropositivity also varies widely based on geographic location and ethnicity. Among Caucasians, 56%-73% of patients with NMO/NMOSD are AQP4-IgG positive, 9,46,47 whereas 33.3% of Caribbean patients, 47% of Italian patients, 63%-90% of Japanese patients, and 70%-76.9% of Chinese patients are seropositive. [48] [49] [50] [51] The wide variability in serostatus may reflect multiple factors, including ethnicity, sex, age, disease activity, immune therapies, and variations in assay techniques. 52 Collectively, the complexities associated with use of AQP4-IgG as a standard biomarker in NMO/NMOSD emphasize the importance of optimization and standardization of assays and clinical diagnostic criteria.
Anti-MOG and other autoantibodies in AQP4-IgGseronegative cases. Recently, additional autoantibodies have gained attention as candidate biomarkers of NMO/NMOSD, particularly in seronegative cases. Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been observed in 20%-40% of pediatric patients with acute disseminated encephalomyelitis, ON, and relapsing demyelination disorders, including NMO/NMOSD. [53] [54] [55] MOG localizes to the outer surface of oligodendrocytes and the myelin sheath. 56 Mader et al. 57 first reported anti-MOG-IgG in a proportion of AQP4-IgG-seronegative adult and pediatric patients with NMO/NMOSD. Most recently, Ramanathan et al. 58 found a strong association between anti-MOG antibodies and bilateral relapsing ON in AQP4-IgG-seronegative patients (sensitivity 69%, specificity 99% in their retrospective adult patient cohort). In their study, MOG-IgG-seropositive patients tended to be younger females with a preceding infection and a relapsing course. Monophasic nature in anti-MOG-seropositive cases has also been reported. 59, 60 Currently, the exclusive expression of AQP4-IgG or MOG-IgG in individual patients with NMO is suggested; however, improved assay conditions in larger randomized cohorts are needed to shed light on MOG-IgG's utility as a biomarker in AQP4-IgG-negative NMO/NMOSD cases and the relationship between these 2 biomarkers.
Other reported autoantibodies in NMO/NMOSD include NMDA-type glutamate receptor (e.g., CV2/ CRMP5) and glycine receptor antibodies.
e1-e4 Antibodies against other aquaporin proteins (e.g., AQP1) also appear to be promising. e5 Autoantibody panels (e.g., presence of anti-acetylcholine receptor, antithyroid, and anti-nuclear antibodies) may be important in understanding the connection between NMO/ NMOSD and coexisting autoimmune diseases such as myasthenia gravis, autoimmune thyroid disorders, and lupus. II. B CELLS B cell dysregulation appears to be at the core of NMO/NMOSD pathogenesis. For instance, B cells expressing anti-AQP4 antibodies in the CSF and elevated levels of circulating plasmablasts are found in patients with acutely active NMO. 17,23,e7 Specific B cell subsets have been implicated as potential biomarker candidates during relapses in patients with NMO. For example, CD138
1 HLA-DR 1 plasmablasts are more abundant in the peripheral blood of patients with NMO and are enriched in the fraction of CSF lymphocytes during a relapse.
e7 From a therapeutic standpoint, efficacy of an anti-CD20 monoclonal antibody (rituximab) may be related to the magnitude of B cell depletion and the repopulation of memory B cells.
e8 Interleukin (IL)-6 signaling plays an important role in antibody-producing plasmablast survival and has an impact on the germinal center maturation of memory B cells in NMO. 17 Alternatively, inhibition of IL-6 signaling may inhibit T helper 17 (T H 17) cell differentiation, an effector T cell type implicated in NMO pathogenesis.
e9 Recent clinical studies also suggest that administration of a monoclonal antibody targeting the IL-6 receptor (tocilizumab) may have clinical benefits in NMO.
e10,e11 Indeed, the depletion of proinflammatory IL-6-secreting B cells may underpin the therapeutic benefit of rituximab, as plasmablasts and plasma cells do not display CD20 and NMO-IgG titers are generally uninfluenced by rituximab therapy.
e12,e13 Future focused analyses of B cell subsets (surface biomarkers, idiotype, and affinity maturation) will be necessary to identify and validate a prognostic or therapeutic B cell biomarker in NMO.
III. CYTOKINES, CHEMOKINES, AND OTHER
MOLECULAR MARKERS OF INFLAMMATION Circulating soluble mediates as well as B and T cell subsets, cells of myeloid lineage, and deposition of immunoglobulin (IgG and IgM) complement present in the target organ suggest the participation of multiple cell types in the pathogenesis of NMO. 29, 30 However, the timing and contribution of each player remain to be determined as we learn more about the pathogenesis of NMO. On the one hand, presence of autoantibodies, high levels of serum IL-5 and CCL24 (eotaxin-2), CCL26 (eotaxin-3) in the CSF, B-cell activating factor (BAFF) in serum and CSF, and infiltration of granulocytes suggest involvement of a T H 2 cellular immune response in NMO/ NMOSD. e14,e15 In addition, there appears to be enhanced expression of T H 17-related (e.g., as IL-17A, IL-6) and T H 1-related (e.g., interferon [IFN]-g) cytokines in some NMO/NMOSD cohorts.
e16,e17
Increased levels of additional inflammatory mediators, including IL-1 receptor antagonist, IL-6, CCL8 (IL-8), IL-13, granulocyte colony-stimulating factor (GCSF), High Mobility Group Box 1 Protein, CXCL13 (BLC), CXCL10 (IP-10), and IL-13-responsive chitinase, have also been detected in the serum or CSF of patients with NMO.
e18,e19 In addition, cytokine and chemokine profile differences between NMO/NMOSD and MS have been examined and may prove useful as future diagnostic biomarkers. e20-e22 Despite the differential expression of these inflammatory markers in the serum of patients with NMO, these markers are also observed in other systemic and inflammatory conditions; thus, the specificity and utility of these biomarkers in NMO remain to be investigated further.
IV. MARKERS OF BBB BREAKDOWN Circulating AQP4-IgG may enter the CNS via the disrupted BBB 28, 30 or may be generated intrathecally. Regardless, factors indicative of BBB integrity may serve as surrogate markers of NMO disease activity. One candidate is matrix metalloproteinase-9 (MMP-9), which participates in degradation of collagen IV and is a major component of cerebral vascular endothelial basement membrane.
e23-e25 Higher serum levels of MMP-9 were reported in patients with NMO compared with patients with MS in a Japanese cohort, and MMP-9 may increase BBB permeability in NMO via an autocrine effect on CNS microvascular endothelial cells.
e26 A second NMO marker of BBB breakdown, vascular endothelial growth factor-A (VEGF-A), counterregulates claudin-5 and occludin at vascular tight junctions. VEGF-A has been implicated in promoting BBB breakdown in demyelinating disorders.
e27-e31
A Japanese study found that patients with MS displayed higher serum VEGF-A levels than healthy controls during an acute relapse, with the highest levels in individuals with opticospinal lesions. Of interest, sera from relapsing patients with NMO induced permeability in an in vitro BBB model, which was reversed by application of an anti-VEGF-A-blocking antibody, suggesting the potential role of VEGF-A in NMO pathology. e32 This effect was higher in sera from AQP4-IgG-seronegative patients with NMOSD than seropositive patients, implying factor(s) other than AQP4-IgG regulate BBB perturbation in NMO.
Other BBB-regulating factors include adhesion molecules, notably intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), which also play important roles in lymphocyte migration into the CNS.
e33-e35 Higher CSF levels of soluble ICAM-1 and soluble VCAM-1 have been reported in patients with relapsing NMO compared with patients with MS or healthy controls and correlate with CSF albumin quotient.
e36 Collectively, markers of BBB breakdown present another avenue of potential biomarkers in NMO/NMOSD, and future studies are warranted to establish their sensitivity/specificity.
V. T H LYMPHOCYTE RESPONSE IN NMO
Another body of emerging evidence points to critical roles for T lymphocyte subsets in the pathogenesis of NMO/ NMOSD. There appears to be a direct relationship between T activation, expansion, and enhanced expression of T H 1, T H 17 cytokines, and APQ4-specific T cells.
e37 Furthermore, presence of APQ4-specific T cells has been observed.
e38,e39
IFN-g-producing T cells were overrepresented compared with IL-4-expressing lymphocytes in the peripheral blood mononuclear cells in patients with OSMS during relapse.
e40,e41 Elevated IL-17 (from T H 17 cells) and CXCL8 levels in CSF were also observed in patients with OSMS and correlated with extent of spinal cord lesions in NMO.
e42 IL-17, IFN-g, and GCSF levels were elevated in the CSF of patients with OSMS regardless of their AQP4-IgG serostatus.
e43 Recent findings also suggest that CD4 1 : CD8 1 T cell ratios may be of interest in understanding NMO/NMOSD pathogenesis and therapeutic efficacy, as shown by reduction in ratio following rituximab therapy during NMO relapse. e44 Moreover, regulatory T cell expansion also correlated with NMO remission following anti-CD20 therapy. e45 However, a comprehensive analysis of the expression, function, and fate of T cell subsets and their corresponding inflammatory mediators in NMO remains to be conducted.
VI. CNS PROTEINS AS BIOMARKERS CNS proteins are detected in sera and CSF of patients with NMO/NMOSD, likely as part of compromised BBB and tissue damage. Neurofilament (NF) heavy-chain levels have been implicated in inflammatory optic neuropathies in NMO/ NMOSD, with high serum NF levels correlating with poor clinical outcome. e46 In addition, GFAP and S100B are astrocytic markers detected in the CSF in several inflammatory CNS disorders, including NMO, and are both elevated in AQP4-IgG-seropositive patients.
e47-e49 CSF and serum levels of S100B correlated with active NMO disease, suggesting that S100B may be a potential biomarker of acute relapse in seropositive NMO. IL-6 and GFAP may also correlate with onset of NMO attack. e50 Other studies have suggested that CSF haptoglobin levels may be a biomarker candidate for diagnosis or disease severity in NMO. e57 It is interesting that the HLA-DRB1*1501 allele, which is associated with MS, does not appear to be associated with NMO.
e58 Also, no common single nucleotide polymorphism in AQP4 appears to be associated with NMO.
e59 Hence, although all of the above examples offer reasonable insights, additional studies in larger cohorts are necessary to explore potential genetic contributions to NMO/NMOSD.
VIII. COMPOSITE BIOMARKER EVALUATION
Beyond assessment of individual biomarkers, it may be useful to explore composite biomarkers and/or biomarker signatures in a complex disease such as NMO/ NMOSD. Pattern analysis applied to proteomic data from NMO/NMOSD and MS has suggested composite signatures that differentiate these diseases, especially during relapse.
e60 Similarly, mass spectrometry and proteome network analyses have been used to generate hypothetical composite biomarkers for potential investigation in NMO/NMOSD, e61 MS, e62 and systemic lupus erythematosus. e63 As with all biomarker discovery or validation efforts, optimal study design is paramount, and any definitive interpretations or conclusions will await prospective masked investigations, preferably among ideally matched and sufficiently large patient cohorts and using optimally standardized methods.
IX. RELATIONSHIP TO CLINICAL DISABILITY Beyond insights into molecular or cellular immunopathology of NMO/NMOSD, further biomarkers are needed to help predict disease activity and outcomes. Current potential markers include BAFF, a proliferationinducing ligand, and osteopontin, which correlate with disability in NMO but not MS.
e15,e64 In addition, CSF levels of CXCL13 (BLC) appear to be elevated in direct proportion to relapse rates and correlate with disability in patients with NMO. e22 While more investigation will be necessary to ascertain their clinical relevance, the intersection of biomarkers and disease status represents an important and unmet patient need.
CONCLUSION Sensitive and specific biomarkers are essential for diagnosis, prediction of relapses, prognosis of disease course, and therapeutic response in NMO. If validated, biomarker candidates identified in recent studies will pave the way to a better understanding of NMO pathogenesis. Moreover, they hold promise for greater diagnostic accuracy and individualized care. AQP4-IgG is the best biomarker of NMO to date; however, standardization and optimization of assays are needed. Future investigation into anti-MOG and other non-AQP4 autoantibodies should adjudicate whether these are clinically useful, especially in the context of AQP4-IgG-seronegative cases. Prospective research into T and B lymphocyte immunobiology, cytokine and chemokine profiles, antioxidants, markers of CNS and BBB damage, and genomics/proteomics are expected to accelerate biomarker discovery and validation. In this regard, collaborative longitudinal international biomarker studies with sufficient sample sizes to ensure statistical power should enhance methodologic standardization and promote consistent diagnostic accuracy worldwide. In turn, these advances will support the most informative clinical trials to improve therapies and address unmet needs for patients with NMO and NMOSD. Although beyond the scope of the current review, future efforts should also include delineation of the utility of imaging and post mortem neuropathologic examination in predicting clinical disability in NMO/NMOSD.
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